Biotechnological companies are currently developing exponentially in industrialised societies, with large portions of help from risk-capital companies, new offerings on stock markets and financial agreements with the major pharmaceutical laboratories.

Biologists, by orientating their research over the last 30 years in the fields of genetics and molecular biology have penetrated into the intimate corners of life itself, and brought about the tools capable of acting both for knowledge, and for change. This research is at the origin of an unprecendented revolution in the world of medicine, a vast potential for new therapeutic treatments, as well as the capacity to increase the length of life for mankind.